Brief: Asahi Kasei Pharma Strengthens Pipeline Through Exclusive Global License Agreement
Feb 25 (Reuters) - Asahi Kasei Corp 3407.T: ASAHI KASEI PHARMA STRENGTHENS PRECLINICAL PIPELINE THROUGH EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH ALCHEMEDICINE FOR NOVEL LEAD COMPOUNDS Source text: ID:nBw8k2pPNa Further company coverage: 3407.T (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on ASAHI KASEI
See all newsBrief: Asahi Kasei Corporation - Subsidiary To Launch Tender Offer For Shares Of Mori-Gumi
Table: ASAHI KASEI -6-MTH group results
Brief: Asahi Kasei Corporation - Announces Cancellation Of Treasury Shares
US FDA approves Asahi Kasei's drug for persistent herpes infections
Table: Asahi Kasei -Q1 group results